These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20959404)

  • 1. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer.
    Wu HH; Wu JY; Cheng YW; Chen CY; Lee MC; Goan YG; Lee H
    Clin Cancer Res; 2010 Nov; 16(21):5200-10. PubMed ID: 20959404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer.
    Tung MC; Wu HH; Cheng YW; Wang L; Chen CY; Yeh SD; Wu TC; Lee H
    Cancer; 2013 Sep; 119(18):3367-76. PubMed ID: 23797467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.
    Chen PM; Cheng YW; Wang YC; Wu TC; Chen CY; Lee H
    Neoplasia; 2014 Nov; 16(11):961-71. PubMed ID: 25425970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
    Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
    Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis.
    Cheng YW; Wu TC; Chen CY; Chou MC; Ko JL; Lee H
    Clin Cancer Res; 2008 Nov; 14(22):7173-9. PubMed ID: 19010833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer.
    Wu DW; Tsai LH; Chen PM; Lee MC; Wang L; Chen CY; Cheng YW; Lee H
    Am J Pathol; 2012 Nov; 181(5):1796-806. PubMed ID: 22982189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
    Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
    Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients.
    Chen SP; Hsu NY; Wu JY; Chen CY; Chou MC; Lee H; Cheng YW
    Ann Thorac Surg; 2013 Apr; 95(4):1196-203. PubMed ID: 23522190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation.
    Cheng YW; Wu MF; Wang J; Yeh KT; Goan YG; Chiou HL; Chen CY; Lee H
    Cancer Res; 2007 Nov; 67(22):10686-93. PubMed ID: 18006810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
    Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
    Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
    Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
    Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
    Bourguignon LYW; Earle C; Shiina M
    Matrix Biol; 2019 May; 78-79():180-200. PubMed ID: 30077625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
    Wong JC; Bathina M; Fiscus RR
    J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6.
    Xu J; Wan X; Chen X; Fang Y; Cheng X; Xie X; Lu W
    Sci Rep; 2016 Jul; 6():28968. PubMed ID: 27364926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.